We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+20.94%
1 Year Est. Return
+80.99%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$5.51B
AUM Growth
+$540M
Cap. Flow
-$18.6M
Cap. Flow %
-0.34%
Top 10 Hldgs %
46.25%
Holding
691
New
31
Increased
112
Reduced
426
Closed
60

Top Sells

Rank Stock Value
1
BTI icon
British American Tobacco
BTI
+$36.2M
2
CLS icon
Celestica
CLS
+$21.9M
3
WMT icon
Walmart Inc
WMT
+$21.5M
4
UNH icon
UnitedHealth
UNH
+$20.7M
5
YUMC icon
Yum China
YUMC
+$14.8M

Sector Composition

Rank Sector Weight
1 Technology 48.98%
2 Communication Services 15.81%
3 Consumer Discretionary 13.07%
4 Healthcare 6.06%
5 Consumer Staples 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMVT icon
376
Immunovant
IMVT
$8.11B
$60.5K ﹤0.01%
3,750
-8
-0.2% -$130
LEGN icon
377
Legend Biotech
LEGN
$3.69B
$59.1K ﹤0.01%
1,812
-280
-13% -$10.3K
VCYT icon
378
Veracyte
VCYT
$4.77B
$58.1K ﹤0.01%
1,693
-291
-15% -$8.35K
SUPN icon
379
Supernus Pharmaceuticals
SUPN
$2.65B
$57.6K ﹤0.01%
1,206
-207
-15% -$8.34K
HIW icon
380
Highwoods Properties
HIW
$3.73B
$57.1K ﹤0.01%
1,795
-121
-6% -$3.7K
BNL icon
381
Broadstone Net Lease
BNL
$4.12B
$56.3K ﹤0.01%
3,148
-187
-6% -$3.22K
SNOW icon
382
Snowflake
SNOW
$103B
$55.7K ﹤0.01%
+247
New +$53K
ALVO icon
383
Alvotech
ALVO
$1.21B
$55.2K ﹤0.01%
6,734
-98
-1% -$835
COLD icon
384
Americold
COLD
$4.13B
$55K ﹤0.01%
4,495
-276
-6% -$4.11K
CDP icon
385
COPT Defense Properties
CDP
$4.35B
$54.8K ﹤0.01%
1,886
-105
-5% -$3.02K
RKT icon
386
Rocket Companies
RKT
$37.5B
$54.2K ﹤0.01%
+2,797
New +$48.8K
MLYS icon
387
Mineralys Therapeutics
MLYS
$2.31B
$54.1K ﹤0.01%
1,426
+152
+12% +$3.29K
TARS icon
388
Tarsus Pharmaceuticals
TARS
$2.6B
$54K ﹤0.01%
908
-70
-7% -$3.45K
GEV icon
389
GE Vernova
GEV
$262B
$53.5K ﹤0.01%
87
-120
-58% -$72.7K
BEAM icon
390
Beam Therapeutics
BEAM
$2.73B
$52.8K ﹤0.01%
2,176
+56
+3% +$1.11K
FOLD
391
DELISTED
Amicus Therapeutics
FOLD
$52.3K ﹤0.01%
6,632
-1,019
-13% -$7.25K
IDYA icon
392
IDEAYA Biosciences
IDYA
$3.5B
$51.3K ﹤0.01%
1,886
-327
-15% -$7.91K
AGIO icon
393
Agios Pharmaceuticals
AGIO
$1.95B
$50.2K ﹤0.01%
1,250
-210
-14% -$7.9K
CNTA
394
DELISTED
Centessa Pharmaceuticals
CNTA
$50.1K ﹤0.01%
2,064
-219
-10% -$3.89K
IBRX icon
395
ImmunityBio
IBRX
$7.8B
$50K ﹤0.01%
20,337
+2,494
+14% +$6.42K
IRON icon
396
Disc Medicine
IRON
$3.03B
$49.4K ﹤0.01%
748
-14
-2% -$833
ADPT icon
397
Adaptive Biotechnologies
ADPT
$3.87B
$49K ﹤0.01%
3,276
-503
-13% -$6.13K
ARQT icon
398
Arcutis Biotherapeutics
ARQT
$3.5B
$48.6K ﹤0.01%
2,580
-416
-14% -$6.56K
ETNB
399
DELISTED
89bio
ETNB
$46.9K ﹤0.01%
3,191
+180
+6% +$1.83K
GRAL
400
GRAIL Inc
GRAL
$3.05B
$45.9K ﹤0.01%
776
-84
-10% -$3.21K

Similar funds

GF Fund Management's Q3 2025 Portfolio in Review

As of Q3 2025, GF Fund Management held 691 positions worth $5.51B, up 11% from $4.97B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q3 2025 filing shows 31 new, 112 increased, 426 reduced and 60 closed positions. Its largest new stake was Bloom Energy: 648,856 shares worth $54.9M. The largest sale was British American Tobacco, an estimated $36.2M.

By sector, the portfolio is most concentrated in Technology at 49% of assets, up from 46% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q3 2025 buy was Bloom Energy: 648,856 shares worth $54.9M.
  • GF Fund Management added most to Lumentum in Q3 2025, an estimated $33.3M increase.
  • GF Fund Management's biggest Q3 2025 reduction was British American Tobacco, cutting an estimated $36.2M.
  • GF Fund Management fully exited Yum China in Q3 2025, selling an estimated $14.8M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.51B portfolio in Q3 2025.
  • GF Fund Management opened 31 new positions and closed 60 in Q3 2025.
  • GF Fund Management's portfolio value rose 11% quarter-over-quarter to $5.51B.

Based on GF Fund Management's 13F filing for Q3 2025, filed 7 Nov 2025.